Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Motor Activity 9Neoplasms 4Breast Neoplasms 3Weight Loss 2Ventricular Dysfunction, Left 1Urinary Incontinence 1Sexual Dysfunction, Physiological 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Leukemia 1Insulin Resistance 1Hypoxia 1Hematologic Neoplasms 1Heart Failure 1Head and Neck Neoplasms 1Fecal Incontinence 1Fatigue 1Cardiotoxicity 1Carcinoma, Renal Cell 1Cachexia 1Brenner Tumor 1Breast Diseases 1Brain Neoplasms 1Bone Metastases 1Body Weight 1

Interventions

Injections 23-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 2alovudine 1Nitroglycerin 1Magnetic Resonance Spectroscopy 1Exercise 1Drug Therapy 1Bacterial Load 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hypoxia × Exercise × Clear all
NCT03365076 2023-01-09

EXIPOX

University Hospital of North Norway

Phase NA Terminated
1 enrolled
Genitourinary

Hypoxia, Motor Activity, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡